Cannabinoid receptor type 1 (CB₁R) inhibits hypothalamic leptin signaling via β-arrestin1 in complex with TC-PTP and...

Area of Science:

• Neuroendocrinology
• Molecular Biology
• Metabolic Regulation

Background:

• Leptin and endocannabinoids have opposing metabolic roles.
• Their molecular interactions, particularly in the hypothalamus, are not fully understood.
• Understanding these interactions is crucial for metabolic disease research.

Purpose of the Study:

• To elucidate the molecular mechanism by which cannabinoid receptor 1 (CB1R) agonists inhibit leptin-induced STAT3 signaling in the hypothalamus.
• To identify key molecular players involved in this inhibitory cross-talk.

Main Methods:

• Utilized mouse models, including knockout mice for beta-arrestin1.
• Employed semi-automated confocal microscopy to measure STAT3 activation in cultured neurons.
• Investigated protein-protein interactions and subcellular localization (e.g., nuclear translocation of beta-arrestin1).

Main Results:

• CB1R agonists diminish leptin-induced STAT3 signaling in hypothalamic neurons.
• This inhibition requires T-cell protein tyrosine phosphatase (TC-PTP) and beta-arrestin1.
• CB1R activation leads to beta-arrestin1 nuclear translocation, binding to STAT3 and TC-PTP.
• The mechanism is independent of cAMP changes.
• CB1R, beta-arrestin1, or TC-PTP deficiency abrogates the inhibitory effect.

Conclusions:

• CB1R activation utilizes beta-arrestin1 to recruit TC-PTP, inhibiting leptin-evoked STAT3 signaling.
• This pathway may limit leptin's anorexigenic effects during heightened endocannabinoid signaling (e.g., fasting, obesity).
• Provides a molecular basis for the interplay between appetite-stimulating and appetite-suppressing pathways.